Post transplant persistence of host cells augments the intensity of acute graft-versus-host disease and level of donor chimerism, an explanation for graft-versus-host disease and rapid displacement of host cells seen following non-myeloablative stem cell transplantation?

Bone Marrow Transplantation

Volumn 38, Issue 5, 2006, Pages 359-364

  Hirshfeld, E ^a   Weiss, L ^a   Kasir, J ^a   Zeira, M ^a   Slavin, S ^a   Shapira, M Y ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Antigen presentation; Chimerism; Graft versus host disease; Non myeloablative stem cell transplantation

Indexed keywords

INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; B CELL LEUKEMIA; CELL DEATH; CHIMERA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DONOR; FEMALE; GRAFT VERSUS LYMPHOMA EFFECT; HOST CELL; LYMPHOCYTE TRANSFUSION; MALE; MOUSE; NONHUMAN; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ANIMALS; FEMALE; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, B-CELL; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MODELS, ANIMAL; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; WHOLE-BODY IRRADIATION;

EID: 33747361860     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705449     Document Type: Article

References (27)

1. Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-4536.
2. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Non-myeloablative transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases. Blood 1998; 91: 756-763.
3. Slavin S, Nagler A, Aker M, Shapira MY, Cividalli G, Or R. Non-myeloablative stem cell transplantation and donor lymphocyte infusion for the treatment of cancer and life-threatening non-malignant disorders. Rev Clin Exp Hematol 2001; 5: 135-146.
4. Slavin S, Fuks Z, Kaplan HS, Strober S. Transplantation of allogeneic bone marrow without graft vs host disease using total lymphoid irradiation. J Exp Med 1978; 147: 963-972.
5. Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 1984; 307: 168-170.
6. Sykes M, Sachs DH. Mixed allogeneic chimerism as an approach to transplantation tolerance. Immunol Today 1988; 9: 23-27.
7. Couriel DR, Saliba RM, Giralt S, Khouri I, Andersson B, de Lima M et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 2004; 10: 178-185.
8. Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J et al. Prevention of graft-versus-host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412-415.
9. Duffner UA, Maeda Y, Cooke KR, Reddy P, Ordemann R, Liu C et al. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol 2004; 172: 7393-7398.
10. Chan GW, Gorgun G, Miller KB, Foss FM. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease. Biol Blood Marrow Transplant 2003; 9: 170-176.
11. Goker H, Haznedaroglu IC, Chao NJ. Acute graft-vs-host disease: pathobiology and management. Exp Hematol 2001; 29: 259-277.
12. Slavin S, Strober S. Spontaneous murine B-cell leukemia. Nature 1978; 272: 624-626.
13. Slavin S, Weiss L, Morecki S, Bassat HB, Leizerowitz R, Gamliel H et al. Ultrastructural, cell membrane and cytogenetic characteristics of B-cell leukemia (BCL1), a murine model of chronic lymphocytic leukemia. Cancer Res 1981; 41: 4162-4166.
14. Pugatsch T, Weiss L, Slavin S. Minimal residual disease in murine B cell leukemia (BCL1) detected by PCR. Leukemia Res 1993; 17: 999-1002.
15. Appelbaum FR, Thomas ED. Treatment of acute leukemia in adults with chemoradiotherapy and bone marrow transplantation. Cancer 1985; 55: 2202-2209.
16. Sinkovics JG, Shullenberger CC. Effect of hematopoietic chimerism on the course of Rauscher's viral mouse leukemia. Proc Am Assoc Cancer Res 1963; 4: 62-72.
17. Boranic M, Tonkovic I. Time pattern of the antileukemia effect of graft-vs-host reaction in mice. I. Cellular events. Cancer Res 1971; 31: 1140-1147.
18. Weiden PL, Fluornoy N, Sanders JE, Sullivan KM, Thomas ED. Antileukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation. Transplantation 1981; 13: 248-251.
19. Slavin S, Or R, Naparstek E, Ackerstein A, Weiss L. Cellular-mediated immunotherapy of leukemia in conjunction with autologous and allogeneic bone marrow transplantation in experimental animals and man. Blood 1988; 72 (Suppl 1): 407a.
20. Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik J, Or R. Allogeneic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 1995; 23: 1553-1562.
21. Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after post allogeneic bone marrow transplantation. Blood 1996; 87: 2195-2204.
22. Ferrara JLM, Cooke KR, Pan L, Krenger W. The immuno-pathophysiology of acute graft-versus-host disease. Stem Cells 1996; 14: 473-489.
23. Weiss L, Slavin S. Prevention and treatment of graft-versus-host disease by down-regulation of anti-host reactivity with veto cells of host origin. Bone Marrow Transplant 1999; 23: 1139-1143.
24. Rachamim N, Gan J, Segall H, Krauthgamer R, Marcus H, Berrebi A et al. Tolerance induction by 'megadose' hematopoietic transplants: Donor-type human CD34 stem cells induce potent specific reduction of host anti-donor cytotoxic T lymphocyte precursors in mixed lymphocyte culture. Transplantation 1998; 65: 1386-1393.
25. Prigozhina TB, Gurevitch O, Slavin S. Nonmyeloablative conditioning to induce bilateral tolerance after allogeneic bone marrow transplantation in mice. Exp Hematol 1999; 27: 1503-1510.
26. Bittencourt MC, Perruche S, Contassot E, Fresnay S, Baron MH, Angonin R et al. Intravenous injection of apoptotic leukocytes enhances bone marrow engraftment across major histocompatibility barriers. Blood 2001; 98: 224-230.
27. Cohen P, Vourka-Karussis U, Weiss L, Slavin S. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens. Immunol 1993; 151: 4803-4810.